Rocket Lab’s shares surged about 30% in a single week last December after reports of a SpaceX IPO valuing that company at up to $1.5 trillion. That rally helped Rocket Lab gain 174% for the full year, pushing its forward revenue multiple to 48 times. Analysts forecast sales could more than double to $1.2 billion by 2027, but such lofty expectations leave little margin for error. Investors should note that sustaining 30% annual growth over multiple years is rare, particularly in a capital-intensive industry where delays or competitive price pressures can swiftly erode projected margins of 40% to 50%.

Rocket Lab’s reusable Neutron rocket has slipped repeatedly, from an original 2024 debut to a likely mid-2026 or later first flight. Each quarter of delay adds roughly $15 million in development costs and increases the risk that the medium-lift offering will miss its window to capture constellation and heavy payload business. Neutron is priced at $50 million to $55 million per mission and can deliver up to 13 000 kg to low-Earth orbit, but further postponements could push initial revenue contributions into 2027 or beyond, undermining near-term cash flows and potentially triggering a sharp pullback in the stock.

In December, Rocket Lab secured an $816 million award from the U.S. Space Force to build 18 missile-tracking satellites under the Tracking Layer Tranche 3 program. This eclipses the company’s previous record $515 million award in 2023 and brings its defense backlog above $2 billion following an earlier $816 million data-relay contract. The new satellites will integrate advanced infrared sensors and Rocket Lab’s proprietary StarLite protection payloads, opening an additional revenue stream as those components are being adopted by competing prime contractors. Spread over four years to deployment in 2029, this contract alone could represent roughly 80% of trailing-twelve-month revenue annually, offering a significant buffer against launch service volatility.